Efficacy and Safety of Low-Dose Everolimus as Maintenance Immunosuppression in Cardiac Transplant Recipients
For cardiac transplant (CTx) recipients, the recommended everolimus (EVL) dose is 0.75 mg bid or 1.5 mg bid and the target trough blood level is 3–8 μg/L. We studied a cohort of 56 CTx patients with chronic kidney disease receiving 0.75 mg bid EVL to maintain blood levels of 5–8 ug/L (designated RD...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Journal of Transplantation |
| Online Access: | http://dx.doi.org/10.1155/2012/976921 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850210043298840576 |
|---|---|
| author | Uwe Fuchs Armin Zittermann Uwe Schulz Jan F. Gummert |
| author_facet | Uwe Fuchs Armin Zittermann Uwe Schulz Jan F. Gummert |
| author_sort | Uwe Fuchs |
| collection | DOAJ |
| description | For cardiac transplant (CTx) recipients, the recommended everolimus (EVL) dose is 0.75 mg bid or 1.5 mg bid and the target trough blood level is 3–8 μg/L. We studied a cohort of 56 CTx patients with chronic kidney disease receiving 0.75 mg bid EVL to maintain blood levels of 5–8 ug/L (designated RD group) and a cohort of 51 CTx patients with chronic kidney disease receiving 0.5 mg bid to maintain blood levels of 3–5 ug/L (designated LD group). The primary endpoint was a composite of death, rejection and premature EVL discontinuation up to 1 year after introduction of EVL. The primary endpoint was reached by 32% of patients in the LD group and by 41.1% of patients in the RD group (𝑃=0.361). Biochemical safety parameters were comparable in both groups. Our results indicate that low-dose EVL may be as effective and safe as regular dose EVL. |
| format | Article |
| id | doaj-art-976df5bafe164dd9916be59c7a5da108 |
| institution | OA Journals |
| issn | 2090-0007 2090-0015 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Transplantation |
| spelling | doaj-art-976df5bafe164dd9916be59c7a5da1082025-08-20T02:09:51ZengWileyJournal of Transplantation2090-00072090-00152012-01-01201210.1155/2012/976921976921Efficacy and Safety of Low-Dose Everolimus as Maintenance Immunosuppression in Cardiac Transplant RecipientsUwe Fuchs0Armin Zittermann1Uwe Schulz2Jan F. Gummert3Clinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center North Rhine-Westphalia, Ruhr University Bochum, Georgstraße 11, 32545 Bad Oeynhausen, GermanyClinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center North Rhine-Westphalia, Ruhr University Bochum, Georgstraße 11, 32545 Bad Oeynhausen, GermanyClinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center North Rhine-Westphalia, Ruhr University Bochum, Georgstraße 11, 32545 Bad Oeynhausen, GermanyClinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center North Rhine-Westphalia, Ruhr University Bochum, Georgstraße 11, 32545 Bad Oeynhausen, GermanyFor cardiac transplant (CTx) recipients, the recommended everolimus (EVL) dose is 0.75 mg bid or 1.5 mg bid and the target trough blood level is 3–8 μg/L. We studied a cohort of 56 CTx patients with chronic kidney disease receiving 0.75 mg bid EVL to maintain blood levels of 5–8 ug/L (designated RD group) and a cohort of 51 CTx patients with chronic kidney disease receiving 0.5 mg bid to maintain blood levels of 3–5 ug/L (designated LD group). The primary endpoint was a composite of death, rejection and premature EVL discontinuation up to 1 year after introduction of EVL. The primary endpoint was reached by 32% of patients in the LD group and by 41.1% of patients in the RD group (𝑃=0.361). Biochemical safety parameters were comparable in both groups. Our results indicate that low-dose EVL may be as effective and safe as regular dose EVL.http://dx.doi.org/10.1155/2012/976921 |
| spellingShingle | Uwe Fuchs Armin Zittermann Uwe Schulz Jan F. Gummert Efficacy and Safety of Low-Dose Everolimus as Maintenance Immunosuppression in Cardiac Transplant Recipients Journal of Transplantation |
| title | Efficacy and Safety of Low-Dose Everolimus as Maintenance Immunosuppression in Cardiac Transplant Recipients |
| title_full | Efficacy and Safety of Low-Dose Everolimus as Maintenance Immunosuppression in Cardiac Transplant Recipients |
| title_fullStr | Efficacy and Safety of Low-Dose Everolimus as Maintenance Immunosuppression in Cardiac Transplant Recipients |
| title_full_unstemmed | Efficacy and Safety of Low-Dose Everolimus as Maintenance Immunosuppression in Cardiac Transplant Recipients |
| title_short | Efficacy and Safety of Low-Dose Everolimus as Maintenance Immunosuppression in Cardiac Transplant Recipients |
| title_sort | efficacy and safety of low dose everolimus as maintenance immunosuppression in cardiac transplant recipients |
| url | http://dx.doi.org/10.1155/2012/976921 |
| work_keys_str_mv | AT uwefuchs efficacyandsafetyoflowdoseeverolimusasmaintenanceimmunosuppressionincardiactransplantrecipients AT arminzittermann efficacyandsafetyoflowdoseeverolimusasmaintenanceimmunosuppressionincardiactransplantrecipients AT uweschulz efficacyandsafetyoflowdoseeverolimusasmaintenanceimmunosuppressionincardiactransplantrecipients AT janfgummert efficacyandsafetyoflowdoseeverolimusasmaintenanceimmunosuppressionincardiactransplantrecipients |